People · Operator
Named in public records as an officer, director or promoter · active 2012–2023 · Biotechnology, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. | — | Biotechnology | Series D+ | $282.2M | $940.0M | 2019 |
| Avalyn Pharma Inc. | — | Biotechnology | Series D+ | $244.0M | $2.7B | 2023 |
| Bolt Biotherapeutics, Inc. | — | Biotechnology | Series C | $178.6M | $432.9M | 2019 |
| Swift Health Systems Inc. | — | Healthtech | Series D+ | $172.6M | $2.0B | 2019 |
| E-scape Bio, Inc. | — | Biotechnology | Series C | $167.1M | $2.8B | 2015 |
| Allakos Inc. | — | Biotechnology | Series D+ | $128.1M | $4.1B | 2012 |
Peter Moldt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Moldt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Asish Xavier | 1 | 18 |
| Peter Thompson | 1 | 16 |
| LEON CHEN | 1 | 15 |
| Jack Nielsen | 1 | 13 |
| Jonathan Leff | 1 | 11 |
| Ketan Patel | 1 | 10 |
| Tiba Aynechi | 1 | 9 |
| Judith Li | 1 | 8 |
| Richard Miller | 1 | 8 |
| James Healy | 1 | 8 |
| Aaron Royston | 1 | 7 |
| Peter Hirth | 1 | 7 |
| Niall O'Donnell | 1 | 7 |
| John McKearn | 1 | 6 |
| Robert Alexander | 1 | 6 |
| Edgar G Engleman | 1 | 5 |
| Farah Champsi | 1 | 5 |
| Mahendra Shah | 1 | 5 |
| Eric Shiozaki | 1 | 4 |
| John Fry | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.